FDA raises new safety concern for anti-HIV didanosine
This article was originally published in Scrip
Executive Summary
The US FDA has warned that the anti-HIV didanosine (Bristol-Myers Squibb's Videx and Videx EC and generics) increase the risk of non-cirrhotic portal hypertension, a potentially fatal liver complication.